Real-world management and long-term outcomes of diabetic macular oedema with good visual acuity.

Autor: Luu KY; Department of Ophthalmology & Vision Sciences, University of California, Davis, Sacramento, CA, USA., Akhter MM; Department of Ophthalmology & Vision Sciences, University of California, Davis, Sacramento, CA, USA., Durbin-Johnson BP; Department of Public Health Sciences, University of California, Davis, Sacramento, CA, USA., Moshiri A; Department of Ophthalmology & Vision Sciences, University of California, Davis, Sacramento, CA, USA., Tran S; Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA., Morse LS; Department of Ophthalmology & Vision Sciences, University of California, Davis, Sacramento, CA, USA., Park SS; Department of Ophthalmology & Vision Sciences, University of California, Davis, Sacramento, CA, USA., Yiu G; Department of Ophthalmology & Vision Sciences, University of California, Davis, Sacramento, CA, USA. gyiu@ucdavis.edu.
Jazyk: angličtina
Zdroj: Eye (London, England) [Eye (Lond)] 2020 Jun; Vol. 34 (6), pp. 1108-1115. Date of Electronic Publication: 2019 Oct 28.
DOI: 10.1038/s41433-019-0647-0
Abstrakt: Purpose: To evaluate the management and long-term outcomes of patients with diabetic macular oedema (DMO) and good initial visual acuity in real-world settings.
Methods: We reviewed 122 eyes of 100 patients with treatment-naive DMO and initial best-corrected visual acuity (BCVA) of 20/25 or better. We assessed clinical characteristics, logMAR BCVA, central subfield thickness (CST), cumulative intravitreal injections and laser treatments at yearly intervals, and characteristics at time of initial treatment. Linear mixed effects models were used to identify predictors of visual outcomes.
Results: At presentation, mean BCVA was 0.057 ± 0.048 logMAR (Snellen 20/23) and mean CST was 288 ± 57 μm. After a median follow-up of 3 years, 51% of eyes underwent treatment. More eyes underwent intravitreal injection as initial treatment (54%), but lasers were initiated at an earlier time and at better BCVA. Final BCVA was associated with better BCVA (P < 0.001) and earlier timing (P = 0.017) at initial treatment, but not CST at first treatment (P = 0.634) or cumulative number of injections or lasers (P = 0.441-0.606).
Conclusion: DMO with good initial visual acuity should be monitored closely, as delay in treatment initiation is associated with worse visual outcomes. BCVA at time of initial treatment is the strongest determinant of final visual acuity.
Databáze: MEDLINE
Externí odkaz: